DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
McDermott DF, Rini BI, Tannir NM. et al.
Treatment-Free Interval (TFI) Following Discontinuation of First-Line Nivolumab Plus Ipilimumab (N+I) or Sunitinib (S) in Patients (Pts) With Advanced Renal Cell Carcinoma (aRCC): CheckMate 214 Analysis.
Annals of Oncology 2018;
DOI: 101093/annonc/mdy283.
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.